Related references
Note: Only part of the references are listed.Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea
Hyeri Yang et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2022)
The burden and risks of emerging complications of diabetes mellitus
Dunya Tomic et al.
NATURE REVIEWS ENDOCRINOLOGY (2022)
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2022)
Type 2 diabetes
Ehtasham Ahmad et al.
LANCET (2022)
Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database
Yoshinori Takeuchi et al.
DIABETES OBESITY & METABOLISM (2021)
2021 Clinical Practice Guidelines for Diabetes Mellitus in Korea
Kyu Yeon Hur et al.
DIABETES & METABOLISM JOURNAL (2021)
Use of oral antidiabetic drugs in Japanese working-age patients with type 2 diabetes mellitus: dosing pattern for metformin initiators
Toshiki Kameda et al.
CURRENT MEDICAL RESEARCH AND OPINION (2020)
Influenza A-associated severe pneumonia in hospitalized patients: Risk factors and NAI treatments
Qianda Zou et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports
A. J. Scheen et al.
DIABETES & METABOLISM (2020)
The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single-centre, retrospective, observational study in Wuhan
Yang Zhang et al.
DIABETES OBESITY & METABOLISM (2020)
Exposure to dipeptidyl-peptidase-4 inhibitors andCOVID-19 among people with type 2 diabetes: A case-control study
Gian Paolo Fadini et al.
DIABETES OBESITY & METABOLISM (2020)
Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients withCOVID-19
Huiqing Li et al.
DIABETES OBESITY & METABOLISM (2020)
Prevalence and impact of diabetes among people infected with SARS-CoV-2
G. P. Fadini et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2020)
Exposure to dipeptidyl-peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta-analysis
Mario Luca Morieri et al.
DIABETES OBESITY & METABOLISM (2020)
Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 (COVID-19) infection
Jing Wu et al.
DIABETES OBESITY & METABOLISM (2020)
Admission fasting blood glucose predicts 30-day poor outcome in patients hospitalized forCOVID-19 pneumonia
Bin Zhang et al.
DIABETES OBESITY & METABOLISM (2020)
Type 2 Diabetes and its Impact on the Immune System
Afiat Berbudi et al.
CURRENT DIABETES REVIEWS (2020)
Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors
Chintan V. Dave et al.
DIABETES OBESITY & METABOLISM (2019)
Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy
Yoojin Noh et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
Jennifer R. Donnan et al.
BMJ OPEN (2019)
Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes
Iliana C. Lega et al.
DIABETES OBESITY & METABOLISM (2019)
Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
Na Wang et al.
DIABETES METABOLIC SYNDROME AND OBESITY (2019)
Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
Soghra Rabizadeh et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2019)
SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
Robert Puckrin et al.
ACTA DIABETOLOGICA (2018)
Diabetes and the occurrence of infection in primary care: a matched cohort study
Waseem Abu-Ashour et al.
BMC INFECTIOUS DISEASES (2018)
Risk of Infection in Type 1 and Type 2 Diabetes Compared With the General Population: A Matched Cohort Study
Iain M. Carey et al.
DIABETES CARE (2018)
SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus
Michael d'Emden et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Mortality from infectious diseases in diabetes
G. Zoppini et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2018)
Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study
Gian Paolo Fadini et al.
DIABETES THERAPY (2018)
Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study
Gian Paolo Fadini et al.
DIABETES THERAPY (2018)
Durability of initial antidiabetic monotherapy and subsequent treatment adjustment patterns among newly treated type 2 diabetes patients
Yoojin Noh et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios
Fernando Gomez-Peralta et al.
DIABETES THERAPY (2018)
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
Peter Ueda et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients
Fei Wang et al.
MEDICINE (2017)
Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies
Yoojin Noh et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2017)
Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
Jiali Liu et al.
SCIENTIFIC REPORTS (2017)
Use of oral antidiabetic agents and risk of community-acquired pneumonia: a nested case-control study
Javier Gorricho et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program
Svetla Gadzhanova et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Community-Acquired Pneumonia in Patients With Diabetes Mellitus: Predictors of Complications and Length of Hospital Stay
Mazen S. Bader et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2016)
Influence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults
Angel Vila-Corcoles et al.
INFECTION (2015)
Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study
Rogier Wvan Der Zanden et al.
PLOS ONE (2015)
SGLT2 inhibitors in the treatment of type 2 diabetes
Farhad M. Hasan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Michael A. Nauck
DRUG DESIGN DEVELOPMENT AND THERAPY (2014)
Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis
Despoina Vasilakou et al.
ANNALS OF INTERNAL MEDICINE (2013)
SGLT inhibitors in management of diabetes
Abd A. Tahrani et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis
Thomas Karagiannis et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review
Kathleen R. Richard et al.
CLINICAL THERAPEUTICS (2011)
Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase
Marjolein J. Willemen et al.
DIABETES CARE (2011)
Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
Gian Paolo Fadini et al.
VASCULAR PHARMACOLOGY (2011)
Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
Renee E. Amori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Share Paper
